Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash from Investing Activities: 2017-2025

Historic Cash from Investing Activities for Denali Therapeutics (DNLI) over the last 9 years, with Sep 2025 value amounting to $57.8 million.

  • Denali Therapeutics' Cash from Investing Activities fell 38.25% to $57.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $406.7 million, marking a year-over-year increase of 316.44%. This contributed to the annual value of -$88.8 million for FY2024, which is 135.60% down from last year.
  • As of Q3 2025, Denali Therapeutics' Cash from Investing Activities stood at $57.8 million, which was down 63.38% from $157.9 million recorded in Q2 2025.
  • Denali Therapeutics' Cash from Investing Activities' 5-year high stood at $172.2 million during Q4 2024, with a 5-year trough of -$453.2 million in Q1 2024.
  • For the 3-year period, Denali Therapeutics' Cash from Investing Activities averaged around $35.9 million, with its median value being $93.7 million (2024).
  • As far as peak fluctuations go, Denali Therapeutics' Cash from Investing Activities surged by 554.45% in 2023, and later slumped by 388.80% in 2024.
  • Over the past 5 years, Denali Therapeutics' Cash from Investing Activities (Quarterly) stood at -$40.8 million in 2021, then crashed by 213.03% to -$127.6 million in 2022, then skyrocketed by 157.27% to $73.0 million in 2023, then surged by 135.75% to $172.2 million in 2024, then tumbled by 38.25% to $57.8 million in 2025.
  • Its Cash from Investing Activities stands at $57.8 million for Q3 2025, versus $157.9 million for Q2 2025 and $18.7 million for Q1 2025.